Pharmacodynamic and pharmacokinetic correlation of muzolimine with and without aluminium hydroxide.
The objective of the reported study was to investigate whether aluminium hydroxide administered in addition to muzolimine interferes with the pharmacodynamics or the pharmacokinetics of the drug. For this purpose a cross-over study in 6 healthy male volunteers was carried out in which each subject received muzolimine and after a wash-out period muzolimine together with Aludrox. To avoid interferences of a psychological nature a third period with placebo was added. The administrations were randomised. The excreted urinary volume was measured, and blood was taken at relevant times in order to follow the pharmacokinetic profile. These are the results: Urinary excretion after the oral administration of muzolimine was within normal limits compared with the literature. There was no change in elimination with respect to either extent or time characteristics after the combined administration of Aludrox. There was no change in the pharmacokinetic profile either.
D000536:Aluminum Hydroxide / Q000494:pharmacology*; D001682:Biological Availability; D004231:Diuresis / Q000187:drug effects; D004359:Drug Therapy, Combination; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000378:metabolism; D007700:Kinetics; D008274:Magnesium / Q000652:urine; D008297:Male; D009156:Muzolimine / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*; D013997:Time Factors
D011720:Pyrazoles; D009156:Muzolimine; D000536:Aluminum Hydroxide; D008274:Magnesium